Record overview
Status and phase
Status: UNKNOWN
Phase: PHASE2
Sponsor: Shandong Cancer Hospital and Institute
Condition: Non-Small-Cell Lung Cancer
NCT03557411
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Unknown Status Signal
Timeline signals: stale_update_signal | primary_completion_date_past_signal | completion_date_past_signal
Results signal: Low Signal
Operational burden: None
Stopped reason
Context when available
No stop reason available in the current public record.